Market: NASD |
Currency: USD
Address: Rue Edouard Belin 12
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
📈 Nyxoah S.A. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$13.76
-
Upside/Downside from Analyst Target:
120.43%
-
Broker Call:
14
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
10-25%
-
Upcoming Earnings Date:
2025-11-14
-
EPS Estimate:
-0.56
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Nyxoah S.A.
| Date | Reported EPS |
|---|
| 2025-11-13 (estimated upcoming) | - |
| 2025-08-18 | -0.55 |
| 2025-05-14 | -0.6 |
| 2025-03-13 | -0.46 |
| 2024-11-06 | -0.5 |
| 2024-08-05 | -0.43 |
| 2024-05-14 | -0.41 |
| 2024-03-05 | -0.38 |
| 2023-11-08 | -0.27 |
| 2023-08-08 | -0.45 |
| 2023-05-16 | -0.46 |
| 2023-03-22 | -0.51 |
| 2022-11-08 | -0.24 |
| 2022-11-07 | -0.21 |
| 2022-08-08 | -0.12 |
| 2022-05-08 | -0.26 |
| 2022-03-23 | -0.15 |
| 2021-08-31 | -0.31 |
📰 Related News & Research
No related articles found for "nyxoah sa".
